TORONTO, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (Upstream: QNTM) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated ...
The Board's primary mission is to provide strategic input, guidance, and recommendations for the company's expanding efforts in optic neuritis and other demyelinating diseases. Dr. Antel joins a CAB ...
TORONTO - Quantum BioPharma Ltd. (NASDAQ:QNTM), a clinical-stage biotech company with a market capitalization of $63.5 million, announced Wednesday the appointment of Dr. Jack Antel as a clinical ...
(MENAFN- GlobeNewsWire - Nasdaq) TORONTO, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (Upstream: QNTM ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results